(KURN) Kuros Biosciences - Ratings and Ratios
Exchange: SW • Country: Switzerland • Currency: CHF • Type: Common Stock • ISIN: CH0325814116
KURN EPS (Earnings per Share)
KURN Revenue
KURN: MagnetOs, Putty, Attrax, Checkmate
Kuros Biosciences AG (SW:KURN) specializes in the development and commercialization of innovative biologic technologies for musculoskeletal care, addressing orthopedic and spinal applications. The company operates across the United States, the European Union, and other international markets, focusing on advancing bone grafting solutions. Its product portfolio includes MagnetOs Granules, a submicron needle-shaped bone graft material designed for enhanced osteoconductivity and osteoinductivity; MagnetOs Putty, a moldable bone graft for filling bony voids in spinal and orthopedic procedures; and Attrax, a biphasic calcium phosphate graft that mimics the structure of natural cancellous bone. Additionally, the company licenses its Checkmate technology, which is designed to enhance bone healing in spinal fusion procedures. Headquartered in Schlieren, Switzerland, Kuros Biosciences was established in 2016 and has since positioned itself as a leader in the field of orthobiologics, with a strong emphasis on proprietary surface technologies that promote bone regeneration.
The company operates through two primary segments: Medical Devices and Legacy Portfolio. The Medical Devices segment focuses on the development and commercialization of its advanced bone grafting products, while the Legacy Portfolio segment manages the licensing of its earlier technologies. Kuros Biosciences has built a reputation for its commitment to innovation, with a focus on addressing unmet clinical needs in the musculoskeletal care market. Its products are designed to provide surgeons with advanced tools for promoting bone healing and regeneration, particularly in complex orthopedic and spinal procedures.
Based on the provided data, Kuros Biosciences AG (SW:KURN) is showing signs of positive momentum in its stock price, with the last price of 28.40 exceeding the SMA 20 (20.96), SMA 50 (20.62), and SMA 200 (20.18). This indicates a bullish trend, with the stock breaking above key resistance levels. The average trading volume over the past 20 days is 275,047, suggesting moderate liquidity. The ATR of 1.39 reflects manageable volatility, which could appeal to investors seeking exposure to growth without extreme price fluctuations.
From a fundamental perspective, the companys market capitalization of 1,012.02M CHF underscores its established presence in the biotechnology sector. However, the lack of P/E and forward P/E ratios, combined with a high P/B ratio of 16.75 and P/S ratio of 13.39, suggests that the market is pricing in significant future growth expectations. The negative return on equity (RoE) of -31.11% indicates current profitability challenges, which may weigh on investor sentiment despite the positive technical indicators. Overall, while the stock shows promise based on its technical momentum, investors should closely monitor the companys ability to translate its innovative portfolio into sustainable profitability.
Additional Sources for KURN Stock
KURN Stock Overview
| Market Cap in USD | 1,181m |
| Sector | Healthcare |
| Industry | Medical Devices |
| GiC Sub-Industry | Health Care Equipment |
| IPO / Inception |
KURN Stock Ratings
| Growth Rating | 77.9 |
| Fundamental | -14.2 |
| Dividend Rating | 0.0 |
| Rel. Strength | 214 |
| Analysts | - |
| Fair Price Momentum | 30.44 CHF |
| Fair Price DCF | 0.62 CHF |
KURN Dividends
Currently no dividends paidKURN Growth Ratios
| Growth Correlation 3m | 66.2% |
| Growth Correlation 12m | 67.8% |
| Growth Correlation 5y | 47.9% |
| CAGR 5y | 67.95% |
| CAGR/Max DD 5y | 1.23 |
| Sharpe Ratio 12m | 1.03 |
| Alpha | 187.04 |
| Beta | 0.784 |
| Volatility | 53.39% |
| Current Volume | 221.1k |
| Average Volume 20d | 142.6k |
As of June 01, 2025, the stock is trading at CHF 26.26 with a total of 221,122 shares traded.
Over the past week, the price has changed by +7.53%, over one month by +1.31%, over three months by +19.09% and over the past year by +199.09%.
Neither. Based on ValueRay´s Fundamental Analyses, Kuros Biosciences is currently (June 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -14.21 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of KURN is around 30.44 CHF . This means that KURN is currently undervalued and has a potential upside of +15.92% (Margin of Safety).
Kuros Biosciences has no consensus analysts rating.
According to our own proprietary Forecast Model, KURN Kuros Biosciences will be worth about 34.9 in June 2026. The stock is currently trading at 26.26. This means that the stock has a potential upside of +32.79%.
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 20.1 | -23.6% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 34.9 | 32.8% |